BioCryst Pharmaceuticals (BCRX) and Its Peers Head-To-Head Analysis

BioCryst Pharmaceuticals (NASDAQ:BCRX) is one of 843 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare BioCryst Pharmaceuticals to related companies based on the strength of its institutional ownership, dividends, risk, earnings, analyst recommendations, profitability and valuation.

Risk & Volatility

BioCryst Pharmaceuticals has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals’ peers have a beta of -1.88, suggesting that their average share price is 288% less volatile than the S&P 500.

Profitability

This table compares BioCryst Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-37.40%	-92.91%	66.56%
BioCryst Pharmaceuticals Competitors	-12,319.70%	-407.93%	-30.95%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for BioCryst Pharmaceuticals and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	1	2	6	0	2.56
BioCryst Pharmaceuticals Competitors	9903	15310	45655	1602	2.54

BioCryst Pharmaceuticals currently has a consensus price target of $20.38, suggesting a potential upside of 167.74%. As a group, “Biotechnology” companies have a potential upside of 126.23%. Given BioCryst Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts clearly believe BioCryst Pharmaceuticals is more favorable than its peers.

Valuation & Earnings

This table compares BioCryst Pharmaceuticals and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
BioCryst Pharmaceuticals	$874.84 million	$263.86 million	-5.36
BioCryst Pharmaceuticals Competitors	$728.85 million	$11.28 million	-18.80

BioCryst Pharmaceuticals has higher revenue and earnings than its peers. BioCryst Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are owned by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

BioCryst Pharmaceuticals beats its peers on 11 of the 13 factors compared.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals is a biotechnology company that discovers, develops and commercializes medicines for rare diseases. Founded in 1986, the company is headquartered in Durham, North Carolina, and focuses on small-molecule treatments. Its principal product is ORLADEYO (berotralstat), an oral medicine for preventing attacks of hereditary angioedema, a rare condition that causes episodes of swelling. BioCryst also develops medicines for rare diseases, including candidates targeting hereditary angioedema and complement-mediated disorders.